Leinco Technologies

Recombinant Human CD40 Ligand (soluble)

Product Code:
LEI-C386
Product Group:
Recombinant Proteins
Regulatory Status:
RUO
Product Types:
  • CD Proteins
  • Cytokines and Other Signalling
  • Immune Checkpoint
  • TNFs
Shipping:
Ambient
Storage:
This lyophilized protein is stable for up to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution and addition of a carrier protein this cytokine may be stored at 2°C to 8°C for one month or for three months at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
1 / 1
❮❯

No additional charges, what you see is what you pay! *

Show prices   How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Antigen Distribution:
CD154 is expressed on activated CD4+ T cells
Format:
This recombinant protein was 0.2 um filtered and lyophilized from a sterile solution of 20 mM PO4, 200 mM NaCl and 0.1 mM EDTA.
Formulation:
This recombinant protein was 0.2 um filtered and lyophilized from a sterile solution of 20 mM PO4, 200 mM NaCl and 0.1 mM EDTA.
Long Description:
CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy. Blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific for human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus plays a significant part in Alzheimer disease pathogenesis.
NCBI Gene:
959
Purity:
>97% by SDS-PAGE and analyzed by silver stain.
Target:
CD40L

References

1. Sch?nbeck, U. et al. (2006) Clin Sci (Lond).111(5):341-7. Article Link 2. Sch?nbeck, U. et al. (2005) Diab Vasc Dis Res. 2(2):81-7. Article Link 3. Ferran, C. et al. (2003) Circulation.108(9):1113-8. Article Link 4. Zhang, G. et al. (2004) Curr. Opin. Struct. Biol. 14:154 5. Lievens, D. et al. (2009) Thromb. Haemost. 102:206 6. Sch?nbeck, U. et al. (2001) Cell. Mol. Life Sci. 58:4 7. Fanslow, WC et al. (1994) Sem. Immunol. 6:267 8. Bhushan, A. et al. (2002) Immunol. Res. 24:311